Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Peginterferon-lambda for the treatment of COVID-19 in outpatients

View ORCID ProfileJordan J. Feld, Christopher Kandel, Mia J. Biondi, Robert A. Kozak, Muhammad Atif Zahoor, Camille Lemieux, Sergio M. Borgia, Andrea K. Boggild, Jeff Powis, Janine McCready, Darrell H. S. Tan, Tiffany Chan, Bryan Coburn, Deepali Kumar, Atul Humar, Adrienne Chan, Braden O’Neil, Seham Noureldin, Joshua Booth, Rachel Hong, David Smookler, Wesam Aleyadeh, Anjali Patel, Bethany Barber, Julia Casey, Ryan Hiebert, Henna Mistry, Ingrid Choong, Colin Hislop, Deanna M. Santer, D. Lorne Tyrrell, Jeffrey S. Glenn, Adam J. Gehring, Harry L.A. Janssen, Bettina Hansen
doi: https://doi.org/10.1101/2020.11.09.20228098
Jordan J. Feld
1Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, University of Toronto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jordan J. Feld
  • For correspondence: Jordan.feld@uhn.ca
Christopher Kandel
2Faculty of Medicine, University of Toronto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mia J. Biondi
1Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, University of Toronto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert A. Kozak
3Sunnybrook Health Sciences Centre, University of Toronto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Muhammad Atif Zahoor
1Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, University of Toronto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Camille Lemieux
4University Health Network, University of Toronto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sergio M. Borgia
5Division of Infectious Diseases, William Osler Health System and McMaster University, Hamilton
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrea K. Boggild
4University Health Network, University of Toronto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeff Powis
6Michael Garron Hospital, University of Toronto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Janine McCready
6Michael Garron Hospital, University of Toronto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Darrell H. S. Tan
7St Michael’s Hospital, University of Toronto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tiffany Chan
8Trillium Health Partners, Toronto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bryan Coburn
4University Health Network, University of Toronto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Deepali Kumar
9Multiorgan Transplant Centre, University Health Network, Toronto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Atul Humar
9Multiorgan Transplant Centre, University Health Network, Toronto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adrienne Chan
3Sunnybrook Health Sciences Centre, University of Toronto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Braden O’Neil
10North York General Hospital, University of Toronto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Seham Noureldin
1Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, University of Toronto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joshua Booth
1Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, University of Toronto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rachel Hong
1Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, University of Toronto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Smookler
1Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, University of Toronto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wesam Aleyadeh
1Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, University of Toronto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anjali Patel
1Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, University of Toronto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bethany Barber
1Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, University of Toronto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julia Casey
1Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, University of Toronto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ryan Hiebert
3Sunnybrook Health Sciences Centre, University of Toronto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Henna Mistry
3Sunnybrook Health Sciences Centre, University of Toronto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ingrid Choong
11Eiger BioPharmaceuticals, Palo Alto, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Colin Hislop
11Eiger BioPharmaceuticals, Palo Alto, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Deanna M. Santer
12The Li Ka Shing Institute of Virology, University of Alberta
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D. Lorne Tyrrell
12The Li Ka Shing Institute of Virology, University of Alberta
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey S. Glenn
13Departments of Medicine and Microbiology & Immunology, Stanford University School of Medicine, Palo Alto, Ca
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adam J. Gehring
1Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, University of Toronto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Harry L.A. Janssen
1Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, University of Toronto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bettina Hansen
1Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, University of Toronto
14Institute of Health Policy, Management and Evaluation, University of Toronto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Summary

Background There are currently no effective treatments for outpatients with coronavirus disease 2019 (COVID-19). Interferon-lambda-1 is a Type III interferon involved in the innate antiviral response with activity against respiratory pathogens.

Methods In this double-blind, placebo-controlled trial, outpatients with laboratory-confirmed COVID-19 were randomized to a single subcutaneous injection of peginterferon-lambda 180μg or placebo within 7 days of symptom onset or first positive swab if asymptomatic. The primary endpoint was proportion negative for SARS-CoV-2 RNA on Day 7 post-injection.

Findings There were 30 patients per arm, with median baseline SARS-CoV-2 viral load of 6.71 (IQR 1.3-8.0) log copies/mL. The decline in SARS-CoV-2 RNA was greater in those treated with peginterferon-lambda than placebo (p=0.04). On Day 7, 24 participants (80%) in the peginterferon-lambda group had an undetectable viral load compared to 19 (63%) in the placebo arm (p=0.15). After controlling for baseline viral load, peginterferon lambda treatment resulted in a 4.12-fold (95CI 1.15-16.7, p=0.029) higher likelihood of viral clearance by Day 7. Of those with baseline viral load above 10E6 copies/mL, 15/19 (79%) in the peginterferon-lambda group were undetectable on Day 7 compared to 6/16 (38%) in the placebo group (p=0.012). Adverse events were similar between groups with only mild reversible transaminase elevations more frequently observed in the peginterferon-lambda group.

Interpretation Peginterferon-lambda accelerated viral decline in outpatients with COVID-19 resulting in a greater proportion with viral clearance by Day 7, particularly in those with high baseline viral load. Peginterferon-lambda may have potential to prevent clinical deterioration and shorten duration of viral shedding.

(NCT04354259)

Funding This study was supported by the Toronto COVID-19 Action Initiative, University of Toronto and the Ontario First COVID-19 Rapid Research Fund. Medication was supplied by Eiger BioPharma.

Research in Context Treatment trials for COVID-19 have largely focused on hospitalized patients and no treatments are approved for people with mild to moderate disease in the outpatient setting. A number of studies in ambulatory populations have been registered but no controlled studies in the outpatient setting have been reported to date (Pubmed Search October 20, 2020, COVID-19 treatment; controlled trials). Uncontrolled case series of hydroxychloroquine with or without azithromycin have been reported with mixed results but no clear signal of efficacy and some concerns raised about cardiac toxicity. Treamtent in the outpatient setting has potential to prevent infected individuals from deteriorating and perhaps more importantly, may shorten the duration of viral shedding, reducing the risk of transmission and the duration required for self-isolation, with significant public health and societal impact.

Added value of this study This is the first study to show an antiviral effect in outpatients with COVID-19. After controlling for baseline viral load, those treated with peginterferon-lambda had a 4.12-fold (95%CI 1.15-16.7, p=0.029) higher odds of viral clearance by Day 7 compared to those who received placebo. The viral load decline was faster with pegterferon-lambda and the effect was most pronounced in those with high viral loads. In individuals with a baseline viral load of 10E6 copies/mL or higher, 15/19 (79%) in the peginterferon-lambda arm cleared by Day 7 compared to 6/16 (38%) (p=0.012) in the placebo arm (OR 6.25, 95%CI 1.49-31.1, p=0.012), translating to a median time to viral clearance of 7 days (95%CI 6.2-7.8 days) with peginterferon-lambda compared to 10 days (95%CI 7.8-12.2 days) with placebo (p=0.038). Those with low viral loads (<10E6 copies/mL) cleared quickly in both groups. Peginterferon-lambda was well-tolerated with a similar side effect profile to placebo and no concerning laboratory adverse events.

Implications of all available evidence There is no currently approved therapy for outpatients with COVID-19. This study showed that peginterferon-lambda accelerated viral clearance, particularly in those with high baseline viral loads, highlighting the importance of quantitative viral load testing in the evaluation of antiviral agents for COVID-19. Treatment early in the course of disease may prevent clinical deterioration and shorenting of the duration of viral shedding may have important public health impact by limiting transmission and reducing the duration required for self-isolation. Additional trials of peginterferon-lambda and other antiviral strategies in the outpatient setting are required.

Competing Interest Statement

JJF reports research support unrelated to this work from Eiger BioPharmaceuticals. BC has received research support unrelated to this work from Nubiyota LLC and Sanofi. IC and CH are employees of Eiger BioPharmaceuticals. JSG is a board member and founder of Eiger BioPharmaceuticals, Inc., in which he has an equity interest, and is an inventor on a patent application for the use of interferon lambda to treat coronavirus infections.

Clinical Trial

NCT04354259

Funding Statement

This study was supported by the Toronto COVID-19 Action Initiative, University of Toronto and the Ontario First COVID-19 Rapid Research Fund. Medication was supplied by Eiger BioPharma. The funding sources did not have any influence on study design, data collection, analysis and interpretation of the data, writing of the report nor the decision to submit for publication.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

University Health Network Research Ethics Board

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ClinicalTrials.gov Identifier: NCT04354259

  • Financial Support: This study was supported by the Toronto COVID-19 Action Initiative, University of Toronto and the Ontario First COVID-19 Rapid Research Fund. Medication was supplied by Eiger BioPharma. The funding sources did not have any influence on study design, data collection, analysis and interpretation of the data, writing of the report nor the decision to submit for publication.

  • Disclosures: JJF reports research support unrelated to this work from Eiger BioPharmaceuticals. BC has received research support unrelated to this work from Nubiyota LLC and Sanofi. IC and CH are employees of Eiger BioPharmaceuticals. JSG is a board member and founder of Eiger BioPharmaceuticals, Inc., in which he has an equity interest, and is an inventor on a patent application for the use of interferon lambda to treat coronavirus infections.

  • Acquisition of Data: JJF, CK, MJB, RAK, CL, SMB, AKB, JP, JM, DHST, TC, DK, AC, BO, SN, JB, RH, DS, AP, WA, BB, DJ, DS, JC, RH, HM, AZ

  • Drafting of the Manuscript: JJF, CK, MJB, RAK, BH, HLAJ

  • Critical Revision of the Manuscript: JJF, CK, MJB, RAK, SMB, AKB, JP, DHST, BC, BO, WA, IC, CH, DMS, DLT, JSG, AJG, HLAJ, BH

  • Statistical Analysis: JJF, CK, MJB, HLAJ, BH

  • Study Supervision: JJF, CK, MJB, RAK, SN, JB, RH, DS, WA, AP, BB, DJ, DS

Data Availability

Data will be available for use through contact with the corresponding author after approval of proposed protocol. Contact: jordan.feld@uhn.ca

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted November 12, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Peginterferon-lambda for the treatment of COVID-19 in outpatients
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Peginterferon-lambda for the treatment of COVID-19 in outpatients
Jordan J. Feld, Christopher Kandel, Mia J. Biondi, Robert A. Kozak, Muhammad Atif Zahoor, Camille Lemieux, Sergio M. Borgia, Andrea K. Boggild, Jeff Powis, Janine McCready, Darrell H. S. Tan, Tiffany Chan, Bryan Coburn, Deepali Kumar, Atul Humar, Adrienne Chan, Braden O’Neil, Seham Noureldin, Joshua Booth, Rachel Hong, David Smookler, Wesam Aleyadeh, Anjali Patel, Bethany Barber, Julia Casey, Ryan Hiebert, Henna Mistry, Ingrid Choong, Colin Hislop, Deanna M. Santer, D. Lorne Tyrrell, Jeffrey S. Glenn, Adam J. Gehring, Harry L.A. Janssen, Bettina Hansen
medRxiv 2020.11.09.20228098; doi: https://doi.org/10.1101/2020.11.09.20228098
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Peginterferon-lambda for the treatment of COVID-19 in outpatients
Jordan J. Feld, Christopher Kandel, Mia J. Biondi, Robert A. Kozak, Muhammad Atif Zahoor, Camille Lemieux, Sergio M. Borgia, Andrea K. Boggild, Jeff Powis, Janine McCready, Darrell H. S. Tan, Tiffany Chan, Bryan Coburn, Deepali Kumar, Atul Humar, Adrienne Chan, Braden O’Neil, Seham Noureldin, Joshua Booth, Rachel Hong, David Smookler, Wesam Aleyadeh, Anjali Patel, Bethany Barber, Julia Casey, Ryan Hiebert, Henna Mistry, Ingrid Choong, Colin Hislop, Deanna M. Santer, D. Lorne Tyrrell, Jeffrey S. Glenn, Adam J. Gehring, Harry L.A. Janssen, Bettina Hansen
medRxiv 2020.11.09.20228098; doi: https://doi.org/10.1101/2020.11.09.20228098

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (179)
  • Allergy and Immunology (433)
  • Anesthesia (99)
  • Cardiovascular Medicine (946)
  • Dentistry and Oral Medicine (178)
  • Dermatology (109)
  • Emergency Medicine (260)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (420)
  • Epidemiology (8978)
  • Forensic Medicine (4)
  • Gastroenterology (419)
  • Genetic and Genomic Medicine (1947)
  • Geriatric Medicine (190)
  • Health Economics (401)
  • Health Informatics (1327)
  • Health Policy (657)
  • Health Systems and Quality Improvement (519)
  • Hematology (212)
  • HIV/AIDS (419)
  • Infectious Diseases (except HIV/AIDS) (10793)
  • Intensive Care and Critical Care Medicine (575)
  • Medical Education (200)
  • Medical Ethics (54)
  • Nephrology (222)
  • Neurology (1824)
  • Nursing (109)
  • Nutrition (272)
  • Obstetrics and Gynecology (352)
  • Occupational and Environmental Health (470)
  • Oncology (997)
  • Ophthalmology (297)
  • Orthopedics (111)
  • Otolaryngology (182)
  • Pain Medicine (126)
  • Palliative Medicine (44)
  • Pathology (265)
  • Pediatrics (579)
  • Pharmacology and Therapeutics (275)
  • Primary Care Research (234)
  • Psychiatry and Clinical Psychology (1895)
  • Public and Global Health (4118)
  • Radiology and Imaging (675)
  • Rehabilitation Medicine and Physical Therapy (366)
  • Respiratory Medicine (548)
  • Rheumatology (224)
  • Sexual and Reproductive Health (190)
  • Sports Medicine (177)
  • Surgery (207)
  • Toxicology (39)
  • Transplantation (109)
  • Urology (80)